



ASX ANNOUNCEMENT

Commercial Update Webinar – US Product Launch Activities

Melbourne, VIC. (4th December 2023) - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”) today announces it will be providing an investor webinar to update the market on its plans and activities relating to the launch of its point-of-care diagnostic tests, FebriDx and ViraDx, in the United States.

Details for a webinar are provided below.

Webinar

Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to invite shareholders and other interested parties to a Shareholder Webinar hosted by CEO Doug Ward and Senior Vice President of Commercial Operations Paul Kase to update the market on its plans and activities relating to the launch of its point of care diagnostic tests, FebriDx and ViraDx in the United States.

The webinar will be held on **Wednesday 6 December 2023 at 11.00am AEDT**.

For the Q&A session, investors are invited to send questions prior to the webinar to:
matt@nwrcommunications.com.au

Register for the webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_LS4Klc_6ReGswOxV_mA6-Q

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those who would prefer to join by phone. A recording will be available at the above link shortly after the conclusion of the live session.

This announcement corrects the title of the earlier announcement titled “Lumos Diagnostics FY2023 Full Year Results Webinar” released on 4 December 2023.

Lumos apologises for the error and any confusion or misunderstanding that it may have generated.

END

This announcement is authorised for release by the Company Secretary.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598